Biomerica, Inc., a global provider of advanced medical diagnostic products, has announced that its inFoods® IBS treatment is now available at Gastro Health’s flagship office in Miami. With plans to expand into other Gastro Health offices in the future, inFoods® IBS offers a revolutionary new approach to alleviate Irritable Bowel Syndrome (IBS) symptoms. Unlike traditional treatments that rely on medications to mask symptoms, inFoods IBS is a personalized and natural treatment approach.
The inFoods IBS test identifies specific foods that can trigger IBS symptoms in individual patients. Once trigger foods have been identified, patients who remove these foods from their diets often experience a significant reduction or elimination of IBS symptoms. A double-blinded placebo-controlled clinical study showed that the inFoods® IBS treatment diet significantly improved several key IBS symptoms, including Abdominal Pain Intensity (API). Symptom improvement in API for patients in the treatment arm versus the placebo arm was similar to, and in some cases better than, the improvement seen from currently available IBS medications but without the drug side effects.
IBS is a digestive disorder that affects an estimated 40 million people in America, making it a leading cause for patient-doctor visits. Traditional treatments often involve the use of medications that only provide temporary relief and can have severe side effects. In contrast, inFoods IBS focuses on the underlying causes of IBS symptoms.
According to Dr. James Leavitt, Director of Clinical Innovation at Gastro Health, “At Gastro Health, we are committed to providing our patients with the most effective and innovative treatments available. inFoods IBS is an innovative personalized approach in the treatment of IBS, offering a safe and effective alternative to traditional drug-based approaches. The personalized inFoods approach to IBS treatment has the potential to change the lives of millions of people suffering from this debilitating condition.”
Zack Irani, CEO of Biomerica, added, “We are excited to partner with Gastro Health to bring inFoods IBS to patients. We believe that personalized approaches are the future of healthcare, and we are proud to offer a solution that addresses the root cause of IBS symptoms without relying on medication. By identifying specific trigger foods for each patient, inFoods IBS creates a personalized plan that not only can relieve symptoms, but also can address the underlying causes of the condition.”
Patients interested in learning more about inFoods IBS and whether it may be a suitable treatment option for them can schedule a consultation with their Gastro Health physician. Gastro Health is one of the leading gastroenterology platforms in the United States and supports practices in Alabama, Florida, Maryland, Massachusetts, Ohio, Virginia, and Washington. Gastro Health strives to provide outstanding medical care and an exceptional healthcare experience. The Gastro Health care teams utilize technology, clinical expertise, and compassionate care to provide a personalized approach to digestive health and overall wellness.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Such forward-looking statements and information involve important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: adoption by physicians and patients of the inFoods IBS test, revenues, commercialization costs, earnings, and cash flows, as well as the Company’s ability to design and enroll patients in a pivotal trial for inFoods IBS test, or delays in the anticipated timing of such clinical trials, meeting with FDA, risks that the costs of a pivotal trial will exceed expectations, and risks that a pivotal trial will not replicate the results of the Company’s endpoint clinical trial. The Company is under no obligation to update any forward-looking statements after publication.
In Other News Around the World: